Dey, Takeda to pay Alabama $6.75M to settle Medicaid fraud charges
Pharma Compliance Alert, January 16, 2008
Dey LP and Takeda Pharmaceuticals North America Inc. have agreed to pay the state of Alabama $6.75 million to settle Medicaid fraud claims, according to a press release from Alabama Attorney General (AG) Troy King.
As part of the settlement, Dey will pay $4.75 million, while Takeda will pay $2 million to settle allegations they fraudulently inflated their reported prices for prescription drugs causing the Alabama Medicaid Agency to overpay pharmacists and doctors for the drugs. Alabama's case against Takeda centered on the diabetes drug Actos, and its case against Dey involved a number of drugs prescribed primarily for pulmonary diseases and asthma.
The AG's lawsuit against 71 other defendants for fraud regarding the pricing of prescription drugs is continuing. The state's complaint against four of the remaining defendants, AstraZeneca Pharmaceuticals LP, AstraZeneca LP, Novartis Pharmaceuticals Corporation, and SmithKline Beecham Corporation d/b/a GlaxoSmithKline, is scheduled to go to trial in February in Montgomery County Circuit Court. The trials against the other defendants will be scheduled later.
Comments
0 comments on “Dey, Takeda to pay Alabama $6.75M to settle Medicaid fraud charges ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- HIPAA Q&A: Level of encryption needed for email
- OB services: Coding inside and outside of the package
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- What does case-mix index mean to you?
- ED-to-inpatient transfers are flawed with safety gaps
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Searched